Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19053424 | CULTURE MEDIUM AND METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN MACROPHAGES AND USE THEREOF | February 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 18945053 | COMPOSITIONS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACID | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18745792 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | June 2024 | February 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18644762 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PRODUCTS | April 2024 | May 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18547750 | METHOD FOR CONSTRUCTING HUMAN PLURIPOTENT STEM CELL-DERIVED LIVER ORGANOID HAVING ENHANCED DRUG METABOLIC POTENTIAL AND LIVER ORGANOID CONSTRUCTED BY SAME METHOD | October 2023 | September 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 17749273 | HUMAN NASOPHARYNGEAL CARCINOMA CELLS DERIVED FROM PATIENT DERIVED XENOGRAFT AND USES THEREOF | May 2022 | November 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17708911 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE | March 2022 | March 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17704947 | TACI BINDING MOLECULES | March 2022 | February 2025 | Allow | 35 | 1 | 1 | No | No |
| 17587552 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | January 2022 | April 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17547323 | METHODS OF PRODUCING ADENOVIRUS | December 2021 | May 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17617481 | MYCOPLASMA MEDIA FORMULATIONS | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17606583 | A METHOD TO PREVENT THE MYELIN ABNORMALITES ASSOCIATED WITH ARGINASE DEFICIENCY | October 2021 | October 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17606502 | TARGET-SPECIFIC CRISPR MUTANT | October 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17602119 | DE NOVO DESIGN OF TUNABLE PH-DRIVEN CONFORMATIONAL SWITCHES | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17599396 | DIFFERENTIATION INDUCER CONTAINING NUCLEUS PULPOSUS PROGENITOR CELL MASTER REGULATOR TRANSCRIPTION FACTORS, METHOD FOR PRODUCING INDUCED NUCLEUS PULPOSUS PROGENITOR CELLS, AND USE OF INDUCED NUCLEUS PULPOSUS PROGENITOR CELLS | September 2021 | April 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17598845 | MOTILE CELL SORTING DEVICE | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17479831 | CENTRIFUGAL MEMBER AND WASHING METHOD | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17438840 | METHODS OF ANTI-TUMOR THERAPY | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17425154 | SYNP35 (PROC8), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS | July 2021 | April 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17422173 | Targeted In Vivo Genome Modification | July 2021 | June 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17356980 | METHODS FOR THE PURIFICATION OF VIRAL VECTORS | June 2021 | August 2024 | Allow | 38 | 2 | 0 | Yes | Yes |
| 17348075 | MULTIFUNCTIONAL POLYMERIC MICROSPHERE/MICROPARTICLE CELL BIOREACTOR SYSTEM AND SORTING PROCESS | June 2021 | April 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17340044 | METHOD FOR RESISTING AGING AND ENHANCING STEMNESS CHARACTERISTICS OF HUMAN MESENCHYMAL STEM CELLS | June 2021 | September 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17295303 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD73 | May 2021 | March 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17291204 | COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17246558 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | April 2021 | March 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17288141 | AAV TRIPLE-PLASMID SYSTEM | April 2021 | April 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17279878 | FRATAXIN EXPRESSION CONSTRUCTS HAVING ENGINEERED PROMOTERS AND METHODS OF USE THEREOF | March 2021 | August 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17277548 | METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS IN DYNAMIC SUSPENSION CULTURE | March 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17196408 | TARGETED MODIFICATION OF RAT GENOME | March 2021 | March 2024 | Allow | 36 | 1 | 0 | No | No |
| 17271635 | GENERATION OF FUNCTIONAL BETA CELLS FROM HUMAN PLURIPOTENT STEM CELL-DERIVED ENDOCRINE PROGENITORS | February 2021 | May 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17271123 | FASL IMMUNOMODULATORY GENE THERAPY COMPOSITIONS AND METHODS FOR USE | February 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17160405 | CELL RECOVERY METHOD | January 2021 | December 2024 | Abandon | 47 | 2 | 0 | No | No |
| 17263124 | HEPATO-BILIARY-PANCREATIC TISSUES AND METHODS OF MAKING SAME | January 2021 | May 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17261928 | COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER | January 2021 | November 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17260936 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | January 2021 | May 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17253742 | METHOD FOR PREPARING PELLETS OF CHONDROCYTES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS, AND USE THEREOF | December 2020 | July 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17050403 | RECOMBINANT IMMUNOGLOBULINS OF A NEW IGG5 CLASS, ENCODED BY THE HUMAN HEAVY CHAIN PSEUDO-GAMMA GENE | October 2020 | May 2025 | Abandon | 55 | 2 | 1 | Yes | No |
| 17041761 | NANOSTRUCTURED MAGENTIC SCAFFOLD FOR CONTROLLING STEM CELL DIFFERENTIATION | September 2020 | April 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17041460 | NUCLEIC ACID MOLECULES AND APPLICATIONS THEREOF IN HUMAN ANTIBODY | September 2020 | August 2024 | Allow | 47 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BATES, KEENAN ALEXANDER.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner BATES, KEENAN ALEXANDER works in Art Unit 1631 and has examined 36 patent applications in our dataset. With an allowance rate of 41.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner BATES, KEENAN ALEXANDER's allowance rate of 41.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BATES, KEENAN ALEXANDER receive 1.14 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by BATES, KEENAN ALEXANDER is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +83.8% benefit to allowance rate for applications examined by BATES, KEENAN ALEXANDER. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.